Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM9ZOMD)

Drug Name

CUDC-101 Drug Info

Synonyms

CUDC-101; 1012054-59-9; CUDC 101; CUDC101; 7-(4-(3-Ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide; UNII-1A7Y9MP123; CHEMBL598797; 1A7Y9MP123; 7-[[4-(3-Ethynylphenylamino)-7-methoxyquinazolin-6-yl]oxy]-N-hydroxyheptanamide; AK174946; 7-((4-(3-Ethynylphenylamino)-7-methoxyquinazolin-6-yl)oxy)-N-hydroxyheptanamide; 7-({4-[(3-ethynylphenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N-hydroxyheptanamide; 7-((4-((3-ethynylphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)-N-hydroxyheptanamide; PubChem19149

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 1	[1]

Cross-matching ID

PubChem CID: 24756910
CAS Number: CAS 1012054-59-9
TTD Drug ID: DM9ZOMD

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Erbb2 tyrosine kinase receptor (HER2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Lapatinib	DM3BH1Y	Breast cancer	2C60-2C65	Approved	[2]
Dacomitinib	DMOH8VY	Non-small-cell lung cancer	2C25.Y	Approved	[3]
BIBW 2992	DMTKD7Q	Non-small-cell lung cancer	2C25.Y	Approved	[4]
Merimepodib	DM0HS92	Breast cancer	2C60-2C65	Approved	[5]
NERATINIB MALEATE	DMEDU7B	HER2/NEU overexpressing breast cancer	2C60-2C65	Approved	[6]
Margetuximab	DMKEY6S	HER2-positive breast cancer	2C60-2C65	Approved	[7]
Trastuzumab	DMZQOUX	Breast cancer	2C60-2C65	Approved	[8]
Tucatinib	DMBESUA	HER2-positive breast cancer	2C60-2C65	Approved	[9]
Pertuzumab	DMHJV0X	Breast cancer	2C60-2C65	Approved	[10]
Masoprocol	DMMVNZ0	Prostate cancer	2C82.0	Approved	[11]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Targeting Epidermal growth factor receptor (EGFR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sorafenib	DMS8IFC	Hepatocellular carcinoma	2C12.02	Approved	[12]
Lapatinib	DM3BH1Y	Breast cancer	2C60-2C65	Approved	[2]
Gefitinib	DM15F0X	Solid tumour/cancer	2A00-2F9Z	Approved	[13]
Erlotinib	DMCMBHA	Non-small-cell lung cancer	2C25.Y	Approved	[14]
Vandetanib	DMRICNP	Solid tumour/cancer	2A00-2F9Z	Approved	[15]
Dacomitinib	DMOH8VY	Non-small-cell lung cancer	2C25.Y	Approved	[16]
BIBW 2992	DMTKD7Q	Non-small-cell lung cancer	2C25.Y	Approved	[4]
SKI-758	DMQ8E9R	Ischemia	8B10-8B11	Approved	[17]
Epidermal growth factor	DMVONE6	Vulnerary	ND56.Z	Approved	[16]
Merimepodib	DM0HS92	Breast cancer	2C60-2C65	Approved	[5]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Epidermal growth factor receptor (EGFR)	TTGKNB4	EGFR_HUMAN	Modulator	[1]
Erbb2 tyrosine kinase receptor (HER2)	TT6EO5L	ERBB2_HUMAN	Modulator	[1]

------------------------------------------------------------------------------------

References

1	A Phase I Study of CUDC-101, a Multitarget Inhibitor of HDACs, EGFR, and HER2, in Combination with Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma. Clin Cancer Res. 2015 Apr 1;21(7):1566-73.
2	Triple negative breast cancer--current status and prospective targeted treatment based on HER1 (EGFR), TOP2A and C-MYC gene assessment. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2009 Mar;153(1):13-7.
3	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7422).
4	Boehringer Ingelheim. Product Development Pipeline. June 2 2009.
5	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
6	2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
7	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
8	Her2/neu is not a commonly expressed therapeutic target in melanoma -- a large cohort tissue microarray study. Melanoma Res. 2004 Jun;14(3):207-10.
9	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
10	Clinical pipeline report, company report or official report of Roche (2009).
11	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
12	Nasopharyngeal carcinoma: Current treatment options and future directions. J Nasopharyng Carcinoma, 2014, 1(16): e16.
13	Gefitinib ('Iressa', ZD1839) and new epidermal growth factor receptor inhibitors. Br J Cancer. 2004 Feb 9;90(3):566-72.
14	Quantitative prediction of fold resistance for inhibitors of EGFR. Biochemistry. 2009 Sep 8;48(35):8435-48.
15	A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
16	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797).
17	Synthesis and Src kinase inhibitory activity of a series of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-7-furyl-3-quinolinecarbonitriles. J Med Chem. 2006 Dec 28;49(26):7868-76.